K2M Group Holdings Inc. (NASDAQ:KTWO) traded up 1% during mid-day trading on Tuesday . The stock traded as high as $18.13 and last traded at $17.34, with a volume of 242,887 shares. The stock had previously closed at $17.17.

Several research firms recently commented on KTWO. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of K2M Group Holdings in a research note on Saturday, April 2nd. Zacks Investment Research downgraded shares of K2M Group Holdings from a “hold” rating to a “sell” rating in a research note on Wednesday, May 4th. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating on shares of K2M Group Holdings in a research note on Tuesday. Northland Securities downgraded shares of K2M Group Holdings from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 3rd. Finally, JMP Securities began coverage on shares of K2M Group Holdings in a research note on Friday, April 8th. They issued an “outperform” rating and a $25.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $22.00.

The firm’s market cap is $715.62 million. The company’s 50-day moving average price is $15.38 and its 200-day moving average price is $14.15.

K2M Group Holdings (NASDAQ:KTWO) last released its earnings results on Monday, May 2nd. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.23) by $0.02. The firm had revenue of $56.20 million for the quarter, compared to analyst estimates of $56 million. During the same period last year, the firm earned ($0.37) earnings per share. The firm’s quarterly revenue was up 11.7% on a year-over-year basis. On average, analysts expect that K2M Group Holdings Inc. will post ($1.10) earnings per share for the current fiscal year.

In other news, Director Carlos A. Ferrer purchased 20,000 shares of the stock in a transaction dated Thursday, May 5th. The shares were purchased at an average price of $11.32 per share, with a total value of $226,400.00. Following the transaction, the director now owns 59,382 shares in the company, valued at approximately $672,204.24. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Gregory S. Cole sold 6,465 shares of the business’s stock in a transaction dated Saturday, May 21st. The shares were sold at an average price of $11.32, for a total transaction of $73,183.80. Following the transaction, the chief financial officer now directly owns 33,233 shares in the company, valued at approximately $376,197.56. The disclosure for this sale can be found here.

Several hedge funds and institutional investors have recently made changes to their positions in the stock. Paradigm Capital Management Inc. NY boosted its position in shares of K2M Group Holdings by 625.2% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 169,700 shares of the medical device company’s stock valued at $3,350,000 after buying an additional 146,300 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of K2M Group Holdings by 1.3% in the fourth quarter. Principal Financial Group Inc. now owns 398,277 shares of the medical device company’s stock valued at $7,862,000 after buying an additional 5,127 shares during the last quarter. OppenheimerFunds Inc. boosted its position in shares of K2M Group Holdings by 13.1% in the fourth quarter. OppenheimerFunds Inc. now owns 908,054 shares of the medical device company’s stock valued at $17,925,000 after buying an additional 105,014 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of K2M Group Holdings by 1.6% in the fourth quarter. New York State Common Retirement Fund now owns 141,690 shares of the medical device company’s stock valued at $2,797,000 after buying an additional 2,170 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in shares of K2M Group Holdings by 3.8% in the fourth quarter. Nationwide Fund Advisors now owns 98,318 shares of the medical device company’s stock valued at $1,941,000 after buying an additional 3,597 shares during the last quarter.

K2M Group Holdings, Inc is a medical device company focused on designing, developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies, such as deformity (primarily scoliosis), trauma and tumor. The Company is engaged in designing, development and commercialization of products for patients suffering from degenerative spinal conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.